UBX - UNITY Biotechnology Inc Stock Price, Fair Value and News

$0.06

Market Closed as of 01 Oct 2025, 04:00 pm ET

UBX Stock Valuation Analysis

Valuation

Max Portfolio %

UBX Price Action

UBX RSI Chart

UBX Stock Valuation Analysis

Valuation

Max Portfolio %

UBX Valuation

UBX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

UBX Fundamentals

UBX Revenue

UBX Earnings

UBX Profitability

UBX Investor Care

Revenue & Growth

How UNITY Biotechnology Inc generates revenue and covers its expenses, based on the latest reported earnings.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

Net sales

Year	Q1	Q2	Q3	Q4
2022	3.6M	2.5M	1.4M	236.0K
2021	-	-	-	4.8M
2017	-	-	-	1.4M

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About UNITY Biotechnology Inc

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.

CEO	Dr. Anirvan Ghosh Ph.D.
WEBSITE	https://unitybiotechnology.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	22